ACGN(Delisted)
Aceragen·NASDAQ
--
--(--)
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ACGN
Aceragen, Inc.
A company that develops therapeutic treatments for pulmonary and rheumatic diseases
505 Eagleview Blvd., Suite 212, 19341, Exton, Pennsylvania 19341
--
Aceragen, Inc., is incorporated in Delaware. Aceragen is a clinical-stage biopharmaceutical company dedicated to transforming the care of people with rare lung and rheumatic diseases. Their portfolio includes late-stage projects based on mature biological principles that they are developing as innovative therapies that address the unmet medical needs of individuals with rare diseases.
Company Financials
EPS
ACGN has released its 2023 Q1 earnings. EPS was reported at -2.94, versus the expected 0, missing expectations. The chart below visualizes how ACGN has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
ACGN has released its 2023 Q1 earnings report, with revenue of 2.47M, reflecting a YoY change of NaN%, and net profit of -21.87M, showing a YoY change of -423.38%. The Sankey diagram below clearly presents ACGN's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
